Role of induction therapy: surgical resection of non-small cell lung cancer after induction therapy

R Taylor Ripley; Valerie W Rusch

doi:10.1016/j.thorsurg.2013.04.004

Role of induction therapy: surgical resection of non-small cell lung cancer after induction therapy

Thorac Surg Clin. 2013 Aug;23(3):273-85. doi: 10.1016/j.thorsurg.2013.04.004. Epub 2013 May 17.

Authors

R Taylor Ripley¹, Valerie W Rusch

Affiliation

¹ Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

PMID: 23931012
DOI: 10.1016/j.thorsurg.2013.04.004

Abstract

Patients with Stage III non-small cell lung cancer are best managed by multimodality therapy. Patients with N2 disease can be treated with induction therapy (usually chemotherapy) followed by surgical resection. Patients whose medical comorbidities preclude surgery should be treated with definitive chemoradiotherapy. T3 or T4 tumors involving the superior sulcus or spine are best managed with induction chemoradiotherapy and surgical resection.

Keywords: Induction therapy; Stage III lung cancer; Surgery.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / therapy*
Chemoradiotherapy, Adjuvant
Combined Modality Therapy
Humans
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Neoadjuvant Therapy
Pneumonectomy